Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

Please urge your two US senators to add their names to a letter to FDA led by Senators Tammy Baldwin (WI) and Roger Marshall (KS). It urges the agency to base any action on compounded hormones on legitimate science, and not the faulty recommendations of the 2020 National Academies of Science, Medicine, and Engineering (NASEM) report on compounded hormones—a report that was colored by bias and a remarkable lack of scientific rigor.

We’ve made it easy via our Voter Voice Platform: You can send our pre-written message as is, or you can customize it as you wish. It will take only a couple of minutes. Our platform will even identify your senators for you, based on your state.

The NASEM report ultimately offered six recommendations which, if implemented by FDA would severely restrict—or eliminate entirely—your ability to compound hormones as a therapy for patients suffering hormone imbalance.

While the FDA has taken no action on compounded hormones yet, we must ensure that they don’t do anything that puts patient health at risk or inhibits your ability to treat your patients. We need your voice in this effort.